Peptron Inc
Company Profile
Business description
Peptron Inc is a biotechnology company engaged in developing fundamental technologies for peptide-based medicines. Its technology includes PeptrEX and SmartDepot. PeptrEX is an automatic system, enabling to synthesize simultaneously from a few to hundred types of peptides. SmartDepot is a proprietary ultrasonic spray drying technology for the preparation of sustained release injectable microsphere formulation of the drug. The group’s research and development products include Luphere Depot for the treatment of prostate cancer and endometriosis, SR Exenatide PT302 AND SR EXENATIDE PT304 for the treatment of type II diabetes, SR Exenatide PT320 and 330 for the treatment of Parkinson’s and Alzheimer’s disease and SR Octreotide for the treatment of acromegaly and carcinoid tumor.
Contact
37-24, Yuseong-daero 1628 beon-gil
Yuseong-gu
Daejeon305811
KORT: +82 423608880
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
138
Stocks News & Analysis
stocks
Investors overly concerned about AI impact on ASX share
stocks
After earnings, is Palantir stock a buy, a sell, or fairly valued?
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,139.90 | 34.50 | -0.38% |
| CAC 40 | 8,342.99 | 19.71 | 0.24% |
| DAX 40 | 24,981.39 | 33.48 | -0.13% |
| Dow JONES (US) | 50,469.83 | 333.96 | 0.67% |
| FTSE 100 | 10,344.59 | 41.64 | -0.40% |
| HKSE | 27,183.15 | 155.99 | 0.58% |
| NASDAQ | 23,190.71 | 47.96 | -0.21% |
| Nikkei 225 | 57,650.54 | 1,286.60 | 2.28% |
| NZX 50 Index | 13,513.68 | 67.31 | 0.50% |
| S&P 500 | 6,969.50 | 4.68 | 0.07% |
| S&P/ASX 200 | 8,867.40 | 44.20 | -0.50% |
| SSE Composite Index | 4,128.37 | 5.28 | 0.13% |